Pentostatin

Generic Name: Pentostatin

Brand Names: Nipent

Drug Type: Small Molecule

Chemical Formula: C_₁₁H_₁₆N_₄O_₄

CAS Number: 53910-25-1

Unique Ingredient Identifier: 395575MZO7

Background: A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.

Indication: For the treatment of hairy cell leukaemia refractory to alpha interferon.

Associated Conditions: Acute Graft-Versus-Host Disease (GVHD), B-Lymphocytic, prolymphocytic leukemia (Kiel Classification) refractory, Chronic Lymphocytic Leukemia, Hairy Cell Leukemia (HCL), Mycosis Fungoides (MF), Sezary Syndrome, Steroid refractory Chronic graft versus host disease

Associated Therapies: -

Clinical Trials

Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2

Completed

Conditions: Stage I Small Lymphocytic Lymphoma
Stage II Chronic Lymphocytic Leukemia
Stage III Small Lymphocytic Lymphoma
Stage IV Chronic Lymphocytic Leukemia
Stage 0 Chronic Lymphocytic Leukemia
Stage I Chronic Lymphocytic Leukemia
Stage II Small Lymphocytic Lymphoma
Stage III Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Stage IV Small Lymphocytic Lymphoma

Interventions: Drug: Cyclophosphamide
Other: Laboratory Biomarker Analysis
Biological: Ofatumumab
Drug: Pentostatin

First Posted Date: 2009-12-02

Last Posted Date: 2018-09-18

Lead Sponsor: Mayo Clinic

Target Recruit Count: 82

Registration Number: NCT01024010

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 1 locations

Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer

Phase 2

Completed

Conditions: Graft-Versus-Host Disease
Renal Cell Carcinoma
Engraftment Syndrome

Interventions: Drug: Pentostatin
Procedure: Donor Lymphocyte Harvest
Procedure: Donor Hematopoietic Stem Cell Harvest
Drug: Sirolimus
Drug: Cyclophosphamide
Procedure: Allogeneic Hematopoietic Stem Cell Transplant (HSCT)
Procedure: Th2 rapa cells
Procedure: Induction Therapy
Procedure: GVHD prophylaxis

First Posted Date: 2009-06-18

Last Posted Date: 2017-09-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT00923845

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2

Completed

Conditions: Lymphoma
Leukemia

Interventions: Biological: bevacizumab
Biological: pegfilgrastim
Biological: rituximab
Drug: cyclophosphamide
Drug: pentostatin

First Posted Date: 2009-01-01

Last Posted Date: 2017-06-15

Lead Sponsor: Mayo Clinic

Target Recruit Count: 68

Registration Number: NCT00816595

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States

Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer

Phase 1

Withdrawn

Conditions: Nonmalignant Neoplasm
Chronic Myeloproliferative Disorders
Leukemia
Myelodysplastic Syndromes
Lymphoma

Interventions: Drug: cyclosporine
Drug: mycophenolate mofetil
Drug: pentostatin
Genetic: cytogenetic analysis
Genetic: fluorescence in situ hybridization
Genetic: protein analysis
Other: flow cytometry
Other: immunoenzyme technique
Other: laboratory biomarker analysis
Other: reduced-intensity transplant conditioning procedure
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation (PBSC)
Radiation: total-body irradiation

First Posted Date: 2009-01-01

Last Posted Date: 2023-08-14

Lead Sponsor: University of Nebraska

Registration Number: NCT00816413

Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation

Phase 2

Terminated

Conditions: Hematologic Neoplasms
Hodgkin's Disease
Lymphoma
Carcinoma, Renal Cell
Leukemia
Multiple Myeloma

Interventions: Drug: Pentostatin
Biological: Alemtuzumab
Procedure: Allogeneic hematopoietic stem cell transplantation

First Posted Date: 2008-06-17

Last Posted Date: 2017-03-31

Lead Sponsor: University of Arizona

Target Recruit Count: 14

Registration Number: NCT00698685

Locations: 🇺🇸
Arizona Cancer Center at UMC North, Tucson, Arizona, United States
🇺🇸
Arizona Cancer Center at UMC North/University Medical Center, Tucson, Arizona, United States

Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2

Completed

Conditions: Leukemia
Lymphoma

Interventions: Biological: alemtuzumab
Biological: rituximab
Drug: pentostatin
Drug: sargramostim

First Posted Date: 2008-04-30

Last Posted Date: 2014-07-01

Lead Sponsor: Mayo Clinic

Target Recruit Count: 41

Registration Number: NCT00669318

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States
🇺🇸
University of Virginia Cancer Center, Charlottesville, Virginia, United States

Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2

Completed

Conditions: Leukemia
Lymphoma

Interventions: Biological: Rituximab
Drug: Cyclophosphamide
Drug: Lenalidomide
Drug: Pentostatin

First Posted Date: 2008-01-28

Last Posted Date: 2020-01-27

Lead Sponsor: Mayo Clinic

Target Recruit Count: 45

Registration Number: NCT00602836

Locations: 🇺🇸
Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸
Mayo Clinic - Jacksonville, Jacksonville, Florida, United States

Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant

Phase 2

Completed

Conditions: Peripheral T-cell Lymphoma
Acute Myelogenous Leukemia
Chronic Lymphocytic Leukemia
Myelodysplastic Syndromes
Chronic Myelogenous Leukemia
Non-Hodgkins Lymphoma
Hodgkins Disease
Acute Lymphocytic Leukemia
Multiple Myeloma

Interventions: Drug: Pentostatin
Radiation: Total-body irradiation (TBI)
Drug: Cyclosporine A (CsA)
Drug: Mycophenolate Mofetil (MMF)
Drug: G-CSF

First Posted Date: 2007-12-12

Last Posted Date: 2023-10-24

Lead Sponsor: University of Nebraska

Target Recruit Count: 76

Registration Number: NCT00571662

Locations: 🇺🇸
University of Nebraska Medical Center, Section of Oncology/Hematology, Omaha, Nebraska, United States

Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer

Phase 1

Completed

Conditions: Leukemia
Lymphoma

Interventions: Biological: filgrastim
Biological: pegfilgrastim
Biological: rituximab
Biological: sargramostim
Drug: cyclophosphamide
Drug: mitoxantrone hydrochloride
Drug: pentostatin
Genetic: fluorescence in situ hybridization
Genetic: gene rearrangement analysis
Genetic: polymerase chain reaction
Genetic: protein expression analysis
Other: flow cytometry
Procedure: biopsy

First Posted Date: 2007-10-18

Last Posted Date: 2016-05-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 50

Registration Number: NCT00546377

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Lymphoma
Leukemia

Interventions: Biological: rituximab
Drug: cyclophosphamide
Drug: pentostatin

First Posted Date: 2007-10-08

Last Posted Date: 2017-08-11

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 49

Registration Number: NCT00541034

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy